Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Johnson & Johnson Pharmaceutical Research & Development
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Phase 3 Randomized, Double-Blind Study of Ceftobiprole Medocaril versus Linezolid Plus Ceftazidime in the Treatment of Nosocomial Pneumonia
Clinical cure rate, defined as the ratio of the number of clinically cured subjects to the total number of subjects in the population at TOC visit.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A randomized withdrawal, active- and placebo-controlled, double-blind, multi-center Phase III trial assessing safety and efficacy of oral CG5503 PR* in subjects with moderate to severe chronic malignant tumor-related pain *PR means Prolonged Release and is the recommended nomenclature for use in EU. ER means Extended Release and is the recommended nomenclature for use in USA. "PR" is synonymous with "ER" and is interchangeable in the protocol
The primary objective of this trial is to evaluate the safety and efficacy orally administered CG5503 PR tablets BID over 4 weeks (Maintenance phase) in subjects with moderate to severe chronic malign...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
Pharmacokinetics and Safety of Doripenem in hospitalized Pediatric Patients from 3 Months to 17 Years of Age
The primary objective of this study is to assess the pharmacokinetics of doripenem and its metabolite, doripenem-M-1, in pediatric subjects 3 months to 17 years of age, inclusive.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
The primary objective of this study was to assess the safety and tolerability of a mebendazole 500-mg chewable tablet formulation in a pediatric population (children 2 to 10 years of age, inclusive).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Phase 3, Randomized, Double-Blind Study Of Ceftobiprole Medocaril Versus Vancomycin With Ceftazidime in The Treatment Of Complicated Skin And Skin Structure Infections
To demonstrate the noninferiority of ceftobiprole/placebo compared with Vancomycin/ceftazidime with respect to clinical cure rate in subjects with complicated skin and skin structure infections (cSSS...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development
MAJ Il y a 4 ans
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia
The primary objective is to compare the safety with respect to the incidence of clinically relevant and objectively confirmed TVEs in 2 dosing regimens of epoetin alfa when used following guidelines f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic Fibrosis
To assess the pharmacokinetics of doripenem after a single 30 mg/kg doripenem 4-hour i.v. infusion administered to pediatric subjects 6 to 17 years of age, inclusive, with cystic fibrosis (CF). Safety...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Johnson & Johnson Pharmaceutical Research & Development, L.L.C
MAJ Il y a 4 ans
Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension
The primary objective of this study is to determine the efficacy of CG5503 immediate release (IR) using the sum of pain intensity difference (SPID) over 48 hours compared to placebo, and to assess the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations